Health Trials

Sickle Cell Anaemia

3

Review clinical trials related to Sickle Cell Anaemia. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Hypoxic Red Blood Cells in Sickle Cell Anemia

The overall objective of this study is to evaluate the effectiveness and safety of transfusing hypoxic red blood cells manufactured with the Hemanext ONE system in patients with sickle cell anemia. The Hemanext ONE device was cleared through the De Novo process in September 2023.

Participants needed: 48
Trial details
Age: 7+Biological sex: AllType: InterventionalSponsor: HemanextUpdated: Jan 7, 2026Locations: 6
Eligibility criteria

Male or female at least 7 years of age; [+4]

Are not exclusively transfused at the site; [+9]

Read more
Status: Not yet recruiting

Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype

SIL-8301 (senicapoc) is being developed for the chronic treatment of patients with sickle cell disease in both adults and children. The purpose of this study is to compare the effects of senicapoc to placebo in patients with sickle cell disease that have had fewer than 2 acute sickle-related painful crises per year over the preceding 2 years, and have a predominantly hemolytic phenotype, defined as presence or history of at least one hemolytic complication and a baseline Hb of 9 g/dL or less, despite receiving hydroxyurea (an oral drug used for treatment of sickle cell disease) as standard of care. Participants will take senicapoc or matching placebo daily and continue on hydroxyurea as prescribed for up to 24 weeks.

Participants needed: 105
Trial details
Phase: Phase 2Age: 16-35Biological sex: AllType: InterventionalSponsor: Biossil Inc.Updated: Dec 15, 2025
Eligibility criteria

Documented diagnosis of sickle cell disease [+5]

Receipt of senicapoc in a previous investigational study [+5]

Read more